Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HaemoneticsHAE +15.93%84 EV-to-OCF is 17.41 as of Aug. 19, 2026, which is 26% below its 10-year median of 23.41. GuruFocus rates HAE with a GF Score™ of 84/100 and a GF Value™ of $85.31 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Haemonetics ranks worse than 70.98% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Haemonetics's Enterprise Value is $5,712 Mil.
Haemonetics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $328 Mil. Therefore, Haemonetics's EV-to-OCF for today is 17.41.
The historical rank and industry rank for Haemonetics's EV-to-OCF or its related term are showing as below:
HAE'
s EV-to-OCF Range Over the Past 10 Years
Min: 10.04 Med: 23.41 Max: 64.72
Current: 17.41
During the past 13 years, the highest EV-to-OCF of Haemonetics was 64.72. The lowest was 10.04. And the median was 23.41.
HAE's EV-to-OCF is ranked worse than 70.98% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 7.78
vs HAE: 17.41
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Haemonetics's PE Ratio (TTM) for today is calculated as:
Haemonetics's share price for today is $104.65.
Haemonetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Haemonetics EV-to-OCF Related Terms
Haemonetics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Haemonetics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Haemonetics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Haemonetics's EV-to-OCF falls into.
Haemonetics's current Enterprise Value is $5,712 Mil.
Haemonetics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $328 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics (HAE) has a EV-to-OCF of 17.41 as of Aug. 19, 2026. This is 26% below median its historical median of 23.41. Over the past decade, Haemonetics' EV-to-OCF has ranged from 10.04 to 64.72. According to the industry distribution chart, Haemonetics ranks #604 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 71%.
Is Haemonetics' EV-to-OCF too high?
Haemonetics' current EV-to-OCF of 17.41 is 26% below median its 10-year median of 23.41. Over the past 10 years, this metric has ranged from a low of 10.04 to a high of 64.72. The Medical Devices & Instruments industry median EV-to-OCF is 7.78. Haemonetics' value of 17.41 is 123.8% above this industry median. Based on the distribution chart, Haemonetics ranks #604 out of 851 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Haemonetics has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' EV-to-OCF compare to IRTC and ITGR?
According to the Medical Devices & Instruments industry distribution chart, Haemonetics ranks #604 out of 851 companies for EV-to-OCF. This places Haemonetics in the lower half of its industry. The industry median EV-to-OCF is 7.78. Haemonetics' value of 17.41 is 123.8% above this benchmark. Historically, Haemonetics' own EV-to-OCF has ranged from 10.04 to 64.72 over the past decade. While the company's 10-year median is 23.41 vs. the industry median of 7.78, Haemonetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.78, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haemonetics's current EV-to-OCF of 17.41 is 123.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haemonetics's current EV-to-OCF is 17.41, which is 26% below median its own 10-year median of 23.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (HAE) is currently considered Modestly Overvalued. The stock's GF Value™ is $85.31, compared to a current price of $104.65 — trading 22.7% above its estimated fair value. The current EV-to-OCF is 17.41, which is 26% below median its 10-year median of 23.41 and 123.8% above the Medical Devices & Instruments industry median of 7.78. Haemonetics' overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Haemonetics (HAE), the current EV-to-OCF is 17.41 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haemonetics (HAE) Overvalued in 2026?
Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued.
The current stock price of $104.65 is trading 22.7% above its estimated GF Value™ of $85.31.
GuruFocus considers Haemonetics to be Modestly Overvalued.
Key valuation signals for HAE:
EV-to-OCF: 17.41 (26% below median its 10-year median of 23.41)
GF Value™: $85.31 vs. price of $104.65 (22.7% above fair value)
Industry Position: 123.8% above the Medical Devices & Instruments median (#604 of 851)
No single metric tells the full story. See the HAE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
84GF Score
Get the complete analysis for HAE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAE has been successfully added to your 
